DistantNews
Support us
🇹🇼 Taiwan /Economy & Trade

Haichang Biotech to List on OTC Market in Late June, Eyes Global Livestock Ambitions

From Liberty Times · () Chinese

Translated from Chinese, summarized and contextualized by DistantNews.

At a glance

News Sources not specified New plan
  • Collagen medical device manufacturer Haichang Biotech (7814) is scheduled to list on the over-the-counter (OTC) market in late June, with an indicative offering price of NT$35.
  • Company Chairman Tsai Kuo-tien stated that Haichang Biotech has prepared its product pipeline for the next decade.
  • The company aims to elevate Taiwan's livestock industry onto the international stage.

Haichang Biotech, a manufacturer of collagen-based medical devices, is preparing for its debut on Taiwan's over-the-counter (OTC) market in late June. The company has set an indicative offering price of NT$35 per share for its upcoming listing.

Chairman Tsai Kuo-tien expressed confidence in the company's future, revealing that Haichang Biotech has meticulously planned its product development pipeline for the coming ten years. This long-term vision underscores the company's commitment to sustained growth and innovation within the medical device sector.

Beyond its immediate market listing, Haichang Biotech harbors ambitions to significantly impact Taiwan's broader economy. Tsai stated the company's goal is to elevate the nation's livestock industry, positioning it for global competitiveness. This initiative suggests a strategic focus on leveraging biotechnology to enhance agricultural and industrial sectors.

DistantNews Editorial

Originally published by Liberty Times in Chinese. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.

More Stories

From Our Blog